Construction of a Macrophage-Tropic Subtype C HIV-1-mGreenLantern Reporter Virus for Studies on HIV-1 Replication and the Impact of Methamphetamine

构建巨噬细胞嗜性C亚型HIV-1-mGreenLantern报告病毒,用于研究HIV-1复制及甲基苯丙胺的影响

阅读:16
作者:Dina Mofed ,Angelo Mandarino ,Xuhong Wu ,Yuekun Lang ,Anjali Gowripalan ,Ganjam V Kalpana ,Vinayaka R Prasad

Abstract

HIV-1 subtype C viruses are responsible for 50% of global HIV burden. However, nearly all currently available reporter viruses widely used in HIV research are based on subtype B. We constructed and characterized a replication-competent HIV-1 subtype C reporter virus expressing mGreenLantern. mGreenLantern sequences were inserted in-frame with Nef ATG in HIV-1IndieC1. As controls, we employed HIV-1IndieC1, HIV-1ADA, and HIV-1NLAD8-GFP-Nef viruses. HIV-1IndieC1-mGreenLantern (HIV-1IndieC1-mGL) exhibited characteristics of the parental HIV-1IndieC1 virus, including its infectivity in TZMbl reporter cells and replication competence in macrophages. To further characterize HIV-1IndieC1-mGL virus, we tested its responsiveness to CCL2 levels, a characteristic feature of subtype B HIV-1 that is missing in subtype C. CCL2 immunodepletion inhibited the production of HIV-1ADA and HIV-1NLAD8-GFP-Nef as expected, but not that of HIV-1IndieC1-mGL, as previously reported. We also tested the effect of methamphetamine, as its effect is mediated by NF-kB and since subtype C viruses carry an additional copy of NF-kB. We found that methamphetamine increased the replication of all viruses tested in macrophages; however, its effect was much more robust for HIV-1IndieC1 and HIV-1IndieC1-mGL. Our studies established that HIV-1IndieC1-mGL retains all the characteristics of the parental HIV-1IndieC1 and can be a useful tool for HIV-1 subtype C investigations. Keywords: CCL2; methamphetamine; replication competent HIV-1 reporter; subtype C HIV-1.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。